Were you diagnosed with Cutaneous T-Cell Lymphoma (CTCL) after using Dupixent (dupilumab)? You may be entitled to compensation.
Patients using Dupixent® (dupilumab) may be more likely to develop a type of cancer known as cutaneous T-cell lymphoma. Dupixent lawsuits claim the manufacturers of this medication failed to adequately warn users about this serious side effect.
Am I Eligible to File a Dupixent Lawsuit?
You may be eligible if you:
- Used Dupixent (dupilumab) as prescribed
- Were later diagnosed with T-Cell Lymphoma, especially Cutaneous T-Cell Lymphoma
- Experienced serious side effects or worsening symptoms
- Are within your state’s statute of limitations
Even if you’re unsure, it’s worth reaching out. We’ll review your case for free and let you know your legal options.
What Is Dupixent (dupilumab)?
Dupixent, also known by its generic name dupilumab, is a prescription drug approved by the FDA to treat conditions like:
- Moderate to severe eczema (atopic dermatitis)
- Asthma
- Chronic rhinosinusitis with nasal polyps
- Eosinophilic esophagitis
Dupixent works by blocking certain proteins involved in inflammation. While many patients have found relief with Dupixent, some have reported devastating side effects — including the development or worsening of Cutaneous T-Cell Lymphoma, a rare but aggressive form of cancer.
What is the Status of Dupixent Lawsuits and FDA Actions?
In March 2025[AJ3] , the FDA announced a formal investigation into Dupixent after receiving more than 300 reports of cutaneous T-cell lymphoma (CTCL)—a rare form of blood cancer that can affect the skin. The agency is evaluating whether new cancer warnings should be added to the drug’s label. This review could strengthen ongoing lawsuits against manufacturers Sanofi and Regeneron, which claim the companies failed to warn that Dupixent might trigger or disguise CTCL, delaying proper cancer diagnoses.
In October 2025, the first Dupixent wrongful death lawsuit was filed, marking a major development in the growing litigation against the drug’s makers, Regeneron and Sanofi-Aventis. The case involves a Tennessee woman who died from T-cell lymphoma just months after beginning Dupixent injections. Her family’s lawsuit claims the drug triggered or sped up the cancer, and that the companies failed to warn doctors and patients about the risk of lymphoma linked to Dupixent use.
What is cutaneous T-cell lymphoma (CTCL)?
Cutaneous T-cell lymphomas (CTCL) are a diverse and complex group of rare cancers. Some types grow slowly and stay in the skin. Less frequently, the cancer spreads from the skin to the blood or a lymph node. Dermatologists often work closely with oncologists (doctors who treat cancer) and other specialists to care for patients who have one of these cancers.
How many types of cutaneous T-cell lymphoma (CTCL) are there?
There are several types. The most common types of cutaneous T-cell lymphoma, also known as CTCL cancer or CTCL, are:
- Mycosis Fungoide (MF) - The most common type, characterized by patches, plaques, and tumors on the skin.
- Sézary Syndrome (SS) - A more aggressive form of MF that affects the blood as well as the skin.
Other more rare types of CTCL include:
- Lymphomatoid papulosis - A benign form of CTCL that causes small, itchy bumps on the skin.
- Granulomatous slack skin - A rare, indolent form of CTCL that causes loose, pendulous folds of skin.
- Anaplastic large cell lymphoma - An aggressive form of CTCL that can spread to other organs.
- Extranodal NK/T-cell lymphoma: A rare type of CTCL that affects the skin and lymph nodes.
- Extranodal NK/T-cell lymphoma, nasal type - A rare, aggressive lymphoma that can affect the skin, among other places.
- Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) - A rare, slow-growing type that causes nodules deep in the fatty layer of the skin, most often on the legs.
- Primary cutaneous peripheral T-cell lymphoma (unspecified) - This is a category for rare entities that do not fit into other classifications.
What Research Links Dupixent to T-Cell Lymphoma?
Multiple studies have indicated that Dupixent may be tied to an increased risk of CTCL.
- A 2019 study published in the Journal of the American Academy of Dermatology, showed multiple patients saw CTCL symptoms accelerate while using dupilumab
- A study published on April 6, 2024 (Hasan et al., 2024), looked at whether people with atopic dermatitis (AD) who were treated with the drug dupilumab had a higher risk of developing cutaneous T-cell lymphoma (CTCL) compared to those who didn’t take the drug. In their first model, which adjusted for age only, they found that people who took dupilumab had a 300% higher risk of getting CTCL compared to those who didn’t (OR 4.10). Even after they adjusted for more factors—like sex, ethnicity, and race, and removed people who had taken certain other immune-suppressing drugs—the risk was still more than two times higher (OR 3.20).
- Another study published in August 2024 using TriNetX data (Mandel et al., 2024) followed a similar method to that employed by Hasan et al. The researchers excluded patients who had other inflammatory diseases or had taken biologic drugs that might be linked to lymphoma. After matching patients by age, race, and sex, they found that people with atopic dermatitis (AD) who were treated with dupilumab had a 350% higher risk of developing cutaneous T-cell lymphoma (CTCL) compared to those who weren’t treated with the drug (RR 4.59).
- In June 2025, a study led by Sheng-Kai Ma and his team looked at the risk of blood cancers in asthma patients who started treatment with dupilumab compared to those who used a common asthma drug combo (ICS/LABA). This study (Ma et al., 2025), using data from TriNetX, did not include anyone with a history of atopic dermatitis (AD). After adjusting for things like age, gender, income, other health problems, and medicine use, the risk of CTCL was more than 4.5 times higher in the dupilumab group. Dupilumab was also linked to an overall increased risk of any type of lymphoma. When the researchers looked only at patients who had taken their medications for at least 16 weeks, the risk numbers went up even more, especially for combined mature T and NK cell lymphomas, a broader group of cancers including CTCL and other subtypes, which was over 14 times higher for dupilumab users.
- Other medical case reports warn that Dupixent may “unmask” or worsen hidden lymphomas mistaken for eczema
How Cory Watson Attorneys Can Help with Your Claim
At Cory Watson Attorneys, we help drug injury victims get the compensation they deserve. We are dedicated to holding big companies who produce and market dangerous drugs accountable, and we strive to protect clients’ best interests by pursuing negligent companies for compensation to help cover medical costs, lost wages, punitive damages and more.
We believe you shouldn’t have to pay for recovering from a medical condition caused by somebody else’s negligence. Our legal team is ready to help you get the compensation you deserve for the suffering you have gone through.